Holen Sie sich die Stockscreener-App
1.99
4.74%
0.09
Handel nachbörslich:
1.99
Schlusskurs vom Vortag:
$1.90
Offen:
$1.7
24-Stunden-Volumen:
571
Relative Volume:
48.82
Marktkapitalisierung:
$N/A
Einnahmen:
$257.55M
Nettoeinkommen (Verlust:
$11.95M
KGV:
2.1868
EPS:
0.91
Netto-Cashflow:
$-9.39M
1W Leistung:
-29.17%
1M Leistung:
-76.15%
6M Leistung:
-81.21%
1J Leistung:
-93.26%
1-Tages-Spanne:
$1.70
$1.99
1-Wochen-Bereich:
$1.70
$1.99
52-Wochen-Spanne:
$1.70
$1.99
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Vergleichen Sie EGRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
1.99 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2018-11-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-31 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-03-21 | Bestätigt | Mizuho | Underperform |
| 2017-11-09 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-06 | Bestätigt | Mizuho | Underperform |
| 2017-07-27 | Bestätigt | Mizuho | Underperform |
| 2017-07-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-05-09 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-01-09 | Herabstufung | Mizuho | Neutral → Underperform |
| 2016-11-16 | Herabstufung | Mizuho | Buy → Neutral |
| 2016-11-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2016-11-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-26 | Bestätigt | Mizuho | Buy |
| 2016-08-16 | Bestätigt | Mizuho | Neutral |
| 2016-06-20 | Herabstufung | Mizuho | Buy → Neutral |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-03-18 | Bestätigt | Mizuho | Buy |
| 2016-02-26 | Bestätigt | Mizuho | Buy |
| 2015-12-09 | Eingeleitet | Mizuho | Buy |
| 2015-07-29 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Eagle Pharmaceuticals Inc Aktie (EGRX) Neueste Nachrichten
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
INVESTOR ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - The AM Reporter
Eagle Pharmaceuticals Shares Turn Positive After Positive 2022 Outlook - marketscreener.com
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender AgreementHagens Berman - ACCESS Newswire
Latham Watkins Advises Eagle Pharmaceuticals in Royalty Monetization With Blue Owl Capital - Latham & Watkins LLP
Eagle Pharmaceuticals Announces $69 Mln Agreement To Monetize Bendeka Royalties - marketscreener.com
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - The Manila Times
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharmaceuticals announces amendment to limited duration stockholder rights plan - Marketscreener.com
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Eagle Pharmaceuticals, Inc. (EGRX) - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX)February 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals, Inc. Enters Third Amended and Restated Credit Agreement - Marketscreener.com
Jane Street Group LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Antiemetics Drugs Market Size & Share Report, 2024 – 2032 - Global Market Insights
Last Week's Biggest Stock Movers: Eagle, Noodles & Co. - AOL
Finanzdaten der Eagle Pharmaceuticals Inc-Aktie (EGRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
1.62%
Kapitalisierung:
|
Volumen (24h):